Keros Therapeutics (NASDAQ:KROS) Sees Large Volume Increase - Still a Buy?

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) saw an uptick in trading volume on Friday . 923,607 shares changed hands during trading, an increase of 110% from the previous session's volume of 439,983 shares.The stock last traded at $19.67 and had previously closed at $18.43.

Wall Street Analysts Forecast Growth

Several brokerages have commented on KROS. Scotiabank lowered their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating on the stock in a research report on Friday. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a report on Thursday, September 12th. HC Wainwright reduced their price objective on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a report on Friday. Wedbush restated an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Guggenheim reaffirmed a "buy" rating and set a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a research report on Wednesday, December 4th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.67.

Keros Therapeutics Trading Up 2.2 %

The business has a fifty day moving average of $59.11 and a 200-day moving average of $52.63. The firm has a market cap of $762.75 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm's revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.33) EPS. On average, equities analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. raised its holdings in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC increased its position in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock worth $24,493,000 after purchasing an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock valued at $12,990,000 after purchasing an additional 199,245 shares in the last quarter. Finally, FMR LLC lifted its position in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.